Last edition
News about "Sintilimab "
Innovent TABOSUN Becomes China's First Approved Domestic Anti CTLA 4 Antibody
Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for TABOSUN (Ipilimumab N01 Injection), marking the country’s first domestically developed anti-CTLA-4 monoclonal antibody and a significant milestone in China’s immuno-oncology landscape.
Sintilimab | 26/12/2025 | By News Bureau
Mankind Pharma, Innovent Biologics to Commercialize Sintilimab for Cancer Care
This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.
Sintilimab | 27/12/2024 | By Aishwarya | 305
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy